Azor and Iris hyperpigmentation - a phase IV clinical study of FDA data

Summary:

We study 4,175 people who take Azor (amlodipine besylate; olmesartan medoxomil) or have Iris hyperpigmentation. No report of Iris hyperpigmentation is found in people who take Azor.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Azor?

Azor has active ingredients of amlodipine besylate; olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 3,922 Azor users. Check the latest studies of Azor.

What is Iris Hyperpigmentation?

Iris hyperpigmentation (unusual darkening of the skin in iris) is found to be associated with 18 drugs and 76 conditions by eHealthMe. Check the latest studies of Iris hyperpigmentation.

On Mar, 26, 2026

No report is found.

Do you take Azor and have Iris hyperpigmentation?

- Check whether Iris hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Azor:

Azor (3,922 reports)

Iris hyperpigmentation treatments and more:

Iris hyperpigmentation (253 reports)

How severe was Iris hyperpigmentation and when was it recovered:

Iris hyperpigmentation in Azor

Expand to all the drugs that have ingredients of amlodipine besylate; olmesartan medoxomil:

Iris hyperpigmentation and drugs with ingredients of amlodipine besylate; olmesartan medoxomil

Browse all side effects of Azor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Iris hyperpigmentation:

Iris hyperpigmentation

Browse all the conditions that are associated with Iris hyperpigmentation:

Iris hyperpigmentation

How the study uses the data?

The study uses data from the FDA. It is based on amlodipine besylate; olmesartan medoxomil (the active ingredients of Azor) and Azor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.